A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

NCT01675973 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Study met stopping criteria specified within protocol.

Conditions

Severe Renal Impairment

Interventions

DRUG: RANEXA

Sponsor

Gilead Sciences